There is on-going development of generic EU CTD Dossier of Repaglinide, tablets, 0.5/1/2 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.
More details at: http://www.rxlist.com/prandin-drug.htm.Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Jobline - Job opportunities published at Farmavita.Net
At the JobLine you can post your job vacancies or search for new job opportunities. We kindly invite all members to post their demand for full-time/part-time jobs, temporary needs, consulting support, project support, internship openings and other opportunities.If you are recruiter or just looking for job ..... find below important presentation which will describe you why are social networks are important to your career.